39 results on '"Griffiths, Megan"'
Search Results
2. A monograph of the African and Madagascan species of Cyperus sect. Incurvi (Cyperaceae)
- Author
-
Griffiths, Megan, Ralimanana, Hélène, Rakotonasolo, Franck, and Larridon, Isabel
- Published
- 2022
- Full Text
- View/download PDF
3. Abstract 15889: An Artificial Intelligence-Derived Pediatric Pulmonary Hypertension Risk Prediction Model From the Pediatric Pulmonary Hypertension Network (PPHNet) Registry
- Author
-
Griffiths, Megan, Manlhiot, Cedric, Chinni, Bhargava K, Sleeper, Lynn A, Abman, Steven, Rosenzweig, Erika, Romer, Lewis H, Mullen, Mary P, Lin, Shili, Benza, raymond, and Everett, Allen D
- Published
- 2023
- Full Text
- View/download PDF
4. Abstract 13857: Slit2/ROBO4 Ligand-Receptor Pair as Novel Biomarkers for Survival in Pulmonary Arterial Hypertension
- Author
-
Blatt, Carly, Yang, Jun, Barnes, Allan, Griffiths, Megan, Damico, Rachel L, Simpson, Catherine, Kolb, Todd, Pauciulo, Michael, Nichols, Bill, Ivy, Dunbar D, Austin, Eric D, Hassoun, Paul, and Everett, Allen D
- Published
- 2023
- Full Text
- View/download PDF
5. Abstract 13128: IGFBP8 as a Novel Biomarker for Hemodynamics and Functional Status in Pulmonary Arterial Hypertension
- Author
-
Blatt, Carly, Schramm, Jennifer, Yang, Jun, Griffiths, Megan, Brandal, Stephanie, Damico, Rachel L, Vaidya, Dhananjay, Simpson, Catherine, Kolb, Todd, Pauciulo, Michael, Nichols, Bill, Ivy, Dunbar D, Austin, Eric D, Hassoun, Paul, and Everett, Allen D
- Published
- 2023
- Full Text
- View/download PDF
6. Improved closed test setup for biodegradation testing of slightly volatile substances in water-sediment systems (OECD 308)
- Author
-
Shrestha, Prasit, Hughes, Christopher B., Camenzuli, Louise, Lyon, Delina, Meisterjahn, Boris, Hennecke, Thomas, Griffiths, Megan, and Hennecke, Dieter
- Published
- 2023
- Full Text
- View/download PDF
7. An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial
- Author
-
Winnett, Georgia, Akbani, Habib, Winearls, Christopher, Wessels, Julie, Ayub, Waqar, Connor, Andrew, Brown, Alison, Moriarty, Jim, Chowdury, Paramit, Griffiths, Megan, Dasgupta, Indranil, Bhandari, Sunil, Doulton, Timothy, Macdougall, Iain, Barratt, Jonathan, Vilar, Enric, Mitra, Sandip, Ramakrishna, Babu, Nicholas, Johann, Ross, Calum, Khwaja, Arif, Hall, Matt, Kirk, Adam, Smith, Stuart, Jesky, Mark, Day, Clara, Alchi, Bassam, Stratton, Jon, Clarke, Helen, Walsh, Stephen, Brown, Rebecca, McCafferty, Kieran, Solomon, Laurie, Ramadoss, Suresh, Basanyake, Kolitha, Lawman, Sarah, Kalra, Philip, Balasubramaniam, Gowrie, Power, Albert, Banerjee, Debasish, Swift, Pauline, Wellberry-Smith, Matt, Goldsmith, Christopher, Ledson, Thomas, Mikhail, Ashraf, Benzimra, Ruth, Bell, Samira, Severn, Alison, Neary, John, Doyle, Arthur, Thomson, Peter, Shivashankar, Girish, Bolton, Stephanie, Quinn, Michael, Maxwell, Peter, Harty, John, Ford, Ian, Anker, Stefan, Farrington, Kenneth, McMurray, John, Tomson, Charles, Wheeler, David, Petrie, Mark, Connolly, Eugene, Jhund, Pardeep, MacDonald, Michael, Mark, Patrick, Walters, Matthew, Peacock, Janet, Isles, Chris, Reddan, Donal, Aziz, Jane, Boyle, Sarah, Burton, Claire, Clarke, Ross, Dinnett, Eleanor, Hillen, Neil, Kean, Sharon, Kerr, Claire, Murray, Heather, Reid, Amanda, Wetherall, Kirsty, Wilson, Robbie, White, Claire, Andani, Sadiq, Thomson, Peter C., Mark, Patrick B., Robertson, Michele, Anker, Stefan D., Jardine, Alan G., Kalra, Philip A., Wheeler, David C., Winearls, Christopher G., and Macdougall, Iain C.
- Published
- 2022
- Full Text
- View/download PDF
8. Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension.
- Author
-
Gao, Li, Skinner, John, Nath, Tanmay, Lin, Qing, Griffiths, Megan, Damico, Rachel L., Pauciulo, Michael W., Nichols, William C., Hassoun, Paul M., Everett, Allen D., and Johns, Roger A.
- Subjects
PULMONARY arterial hypertension ,RESISTIN ,OVERALL survival ,PULMONARY hypertension ,SINGLE nucleotide polymorphisms ,RIGHT ventricular hypertrophy ,BIOMARKERS - Abstract
Background: Abnormal remodeling of distal pulmonary arteries in patients with pulmonary arterial hypertension (PAH) leads to progressively increased pulmonary vascular resistance, followed by right ventricular hypertrophy and failure. Despite considerable advancements in PAH treatment prognosis remains poor. We aim to evaluate the potential for using the cytokine resistin as a genetic and biological marker for disease severity and survival in a large cohort of patients with PAH. Methods: Biospecimens, clinical, and genetic data for 1121 adults with PAH, including 808 with idiopathic PAH (IPAH) and 313 with scleroderma-associated PAH (SSc-PAH), were obtained from a national repository. Serum resistin levels were measured by ELISA, and associations between resistin levels, clinical variables, and single nucleotide polymorphism genotypes were examined with multivariable regression models. Machine-learning (ML) algorithms were applied to develop and compare risk models for mortality prediction. Results: Resistin levels were significantly higher in all PAH samples and PAH subtype (IPAH and SSc-PAH) samples than in controls (P <.0001) and had significant discriminative abilities (AUCs of 0.84, 0.82, and 0.91, respectively; P <.001). High resistin levels (above 4.54 ng/mL) in PAH patients were associated with older age (P =.001), shorter 6-min walk distance (P =.001), and reduced cardiac performance (cardiac index, P =.016). Interestingly, mutant carriers of either rs3219175 or rs3745367 had higher resistin levels (adjusted P =.0001). High resistin levels in PAH patients were also associated with increased risk of death (hazard ratio: 2.6; 95% CI: 1.27–5.33; P <.0087). Comparisons of ML–derived survival models confirmed satisfactory prognostic value of the random forest model (AUC = 0.70, 95% CI: 0.62–0.79) for PAH. Conclusions: This work establishes the importance of resistin in the pathobiology of human PAH. In line with its function in rodent models, serum resistin represents a novel biomarker for PAH prognostication and may indicate a new therapeutic avenue. ML-derived survival models highlighted the importance of including resistin levels to improve performance. Future studies are needed to develop multi-marker assays that improve noninvasive risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Cardiac Dysfunction Biomarkers Are Associated With Potential for Successful Separation From Extracorporeal Membrane Oxygenation in Children
- Author
-
Coletti, Kristen, Griffiths, Megan, Nies, Melanie, Brandal, Stephanie, Everett, Allen D., and Bembea, Melania M.
- Published
- 2023
- Full Text
- View/download PDF
10. Abstract 15389: Insulin Like Growth Factor Binding Proteins 1 and 2 Are Prognostic Survival Markers in Intermediate Risk Pulmonary Arterial Hypertension
- Author
-
Griffiths, Megan, Simpson, Catherine, Yang, Jun, Torres, Guillermo, Vaidya, Dhananjay, Brandal, Stephanie, Pauciulo, Michael, Damico, Rachel L, Hassoun, Paul, Ivy, Dunbar D, Austin, Eric, Rosenzweig, Erika, Nichols, Bill, and Everett, Allen D
- Published
- 2022
- Full Text
- View/download PDF
11. Abstract 13688: Low-Affinity Insulin-Like Growth Factor Binding Protein 7 and Its Association With Pulmonary Arterial Hypertension Severity and Survival
- Author
-
Torres-Viera, Guillermo, Lancaster, Andrew, Yang, Jun, Griffiths, Megan, Brandal, Stephanie, Damico, Rachel L, Everett, Allen D, Ivy, Dunbar D, Austin, Eric, Simpson, Catherine, Vaidya, Dhananjay, and Nichols, Bill
- Published
- 2022
- Full Text
- View/download PDF
12. Advances in understanding bat infection dynamics across biological scales.
- Author
-
Sánchez, Cecilia A., Phelps, Kendra L., Frank, Hannah K., Geldenhuys, Marike, Griffiths, Megan E., Jones, Devin N., Kettenburg, Gwenddolen, Lunn, Tamika J., Moreno, Kelsey R., Mortlock, Marinda, Vicente-Santos, Amanda, Víquez-R, Luis R., Kading, Rebekah C., Markotter, Wanda, Reeder, DeeAnn M., and Olival, Kevin J.
- Subjects
BATS ,EPIDEMIOLOGICAL research ,INFECTION ,RABIES virus - Abstract
Over the past two decades, research on bat-associated microbes such as viruses, bacteria and fungi has dramatically increased. Here, we synthesize themes from a conference symposium focused on advances in the research of bats and their microbes, including physiological, immunological, ecological and epidemiological research that has improved our understanding of bat infection dynamics at multiple biological scales. We first present metrics for measuring individual bat responses to infection and challenges associated with using these metrics. We next discuss infection dynamics within bat populations of the same species, before introducing complexities that arise in multi-species communities of bats, humans and/or livestock. Finally, we outline critical gaps and opportunities for future interdisciplinary work on topics involving bats and their microbes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Toxicity and risk of plant-produced alkaloids to Daphnia magna
- Author
-
Griffiths, Megan R., Strobel, Bjarne W., Hama, Jawameer R., and Cedergreen, Nina
- Published
- 2021
- Full Text
- View/download PDF
14. Management of paediatric sleep-disordered breathing.
- Author
-
Springford, Laurie R., Griffiths, Megan, and Bajaj, Yogesh
- Abstract
Paediatric sleep-disordered breathing is a common condition which varies in severity from snoring to obstructive sleep apnoea. Paediatric sleep-disordered breathing is usually diagnosed clinically, with investigations such as polysomnography reserved for more complex cases. Management can involve watching and waiting, medical or adjunct treatments and adenotonsillectomy. National working groups have sought to standardise the pathway for surgery and improve the management of surgical and anaesthetic complications. Current guidelines use age, weight and comorbidities to stratify risk for these surgical cases. This article summarises these recommendations and outlines the important factors that indicate cases that may be more suitable for management in secondary and tertiary units. Appropriate case selection will reduce pressure on tertiary units while maintaining training opportunities in district general hospitals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Metabolomic Differences in Connective Tissue Disease–Associated Versus Idiopathic Pulmonary Arterial Hypertension in the PVDOMICS Cohort.
- Author
-
Simpson, Catherine E., Hemnes, Anna R., Griffiths, Megan, Grunig, Gabriele, Tang, W. H. Wilson, Garcia, Joe G. N., Barnard, John, Comhair, Suzy A., Damico, Rachel L., Mathai, Stephen C., and Hassoun, Paul M.
- Subjects
LIPID metabolism ,PULMONARY arterial hypertension ,BLOOD pressure ,PULMONARY circulation ,METABOLOMICS ,RIGHT heart ventricle ,MACHINE learning ,REGRESSION analysis ,PULMONARY artery ,CONNECTIVE tissue diseases ,VASODILATORS ,SEX hormones ,RESEARCH funding ,PHENOTYPES ,LONGITUDINAL method ,ALGORITHMS ,FATTY acids ,DISEASE complications - Abstract
Objective: Patients with connective tissue disease–associated pulmonary arterial hypertension (CTD‐PAH) experience worse survival and derive less benefit from pulmonary vasodilator therapies than patients with idiopathic PAH (IPAH). We sought to identify differential metabolism in patients with CTD‐PAH versus patients with IPAH that might underlie these observed clinical differences. Methods: Adult participants with CTD‐PAH (n = 141) and IPAH (n = 165) from the Pulmonary Vascular Disease Phenomics (PVDOMICS) study were included. Detailed clinical phenotyping was performed at cohort enrollment, including broad‐based global metabolomic profiling of plasma samples. Participants were followed prospectively for ascertainment of outcomes. Supervised and unsupervised machine learning algorithms and regression models were used to compare CTD‐PAH versus IPAH metabolomic profiles and to measure metabolite‐phenotype associations and interactions. Gradients across the pulmonary circulation were assessed using paired mixed venous and wedged samples in a subset of 115 participants. Results: Metabolomic profiles distinguished CTD‐PAH from IPAH, with patients with CTD‐PAH demonstrating aberrant lipid metabolism with lower circulating levels of sex steroid hormones and higher free fatty acids (FAs) and FA intermediates. Acylcholines were taken up by the right ventricular–pulmonary vascular (RV‐PV) circulation, particularly in CTD‐PAH, while free FAs and acylcarnitines were released. In both PAH subtypes, dysregulated lipid metabolites, among others, were associated with hemodynamic and RV measurements and with transplant‐free survival. Conclusions: CTD‐PAH is characterized by aberrant lipid metabolism that may signal shifted metabolic substrate utilization. Abnormalities in RV‐PV FA metabolism may imply a reduced capacity for mitochondrial beta oxidation within the diseased pulmonary circulation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Developing transmissible vaccines for animal infections.
- Author
-
Streicker, Daniel G., Griffiths, Megan E., Antia, Rustom, Bergner, Laura, Bowman, Peter, dos Santos de Moraes, Maria Vitoria, Esvelt, Kevin, Famulare, Mike, Gilbert, Amy, He, Biao, Jarvis, Michael A., Kennedy, David A., Kuzma, Jennifer, Wanyonyi, Carolyne Nasimiyu, Remien, Christopher, Rocke, Tonie, Rosenke, Kyle, Schreiner, Courtney, Sheen, Justin, and Simons, David
- Subjects
- *
VACCINE development , *WHITE-nose syndrome , *EBOLA virus disease ,RABBIT diseases - Abstract
The article discusses the potential of transmissible vaccines (TVs) to revolutionize public health, wildlife conservation, and animal welfare by immunizing wildlife populations at scales necessary to interrupt pathogen transmission. Topics include vaccine safety criteria, staged development with established checkpoints, and equitable partnerships with international governance.
- Published
- 2024
- Full Text
- View/download PDF
17. Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension.
- Author
-
Simpson, Catherine E., Ambade, Anjira S., Harlan, Robert, Roux, Aurelie, Aja, Susan, Graham, David, Shah, Ami A., Hummers, Laura K., Hemnes, Anna R., Leopold, Jane A., Horn, Evelyn M., Berman-Rosenzweig, Erika S., Grunig, Gabriele, Aldred, Micheala A., Barnard, John, Comhair, Suzy A. A., Tang, W. H. Wilson, Griffiths, Megan, Rischard, Franz, and Frantz, Robert P.
- Subjects
PULMONARY arterial hypertension ,KYNURENINE ,TRYPTOPHAN ,SYSTEMIC scleroderma ,METABOLISM ,CARDIAC catheterization ,RIGHT ventricular hypertrophy - Abstract
Understanding metabolic evolution underlying pulmonary arterial hypertension (PAH) development may clarify pathobiology and reveal disease-specific biomarkers. Patients with systemic sclerosis (SSc) are regularly surveilled for PAH, presenting an opportunity to examine metabolic change as disease develops in an at-risk cohort. We performed mass spectrometry-based metabolomics on longitudinal serum samples collected before and near SSc-PAH diagnosis, compared with time-matched SSc subjects without PAH, in a SSc surveillance cohort. We validated metabolic differences in a second cohort and determined metabolite-phenotype relationships. In parallel, we performed serial metabolomic and hemodynamic assessments as the disease developed in a preclinical model. For differentially expressed metabolites, we investigated corresponding gene expression in human and rodent PAH lungs. Kynurenine and its ratio to tryptophan (kyn/trp) increased over the surveillance period in patients with SSc who developed PAH. Higher kyn/trp measured two years before diagnostic right heart catheterization increased the odds of SSc-PAH diagnosis (OR 1.57, 95% CI 1.05-2.36, P = 0.028). The slope of kyn/trp rise during SSc surveillance predicted PAH development and mortality. In both clinical and experimental PAH, higher kynurenine pathway metabolites correlated with adverse pulmonary vascular and RV measurements. In human and rodent PAH lungs, expression of TDO2, which encodes tryptophan 2,3 dioxygenase (TDO), a protein that catalyzes tryptophan conversion to kynurenine, was significantly upregulated and tightly correlated with pulmonary hypertensive features. Upregulated kynurenine pathway metabolism occurs early in PAH, localizes to the lung, and may be modulated by TDO2. Kynurenine pathway metabolites may be candidate PAH biomarkers and TDO warrants exploration as a potential novel therapeutic target. NEW & NOTEWORTHY: Our study shows an early increase in kynurenine pathway metabolism in at-risk subjects with systemic sclerosis who develop pulmonary arterial hypertension (PAH). We show that kynurenine pathway upregulation precedes clinical diagnosis and that this metabolic shift is associated with increased disease severity and shorter survival times. We also show that gene expression of TDO2, an enzyme that generates kynurenine from tryptophan, rises with PAH development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Exercise training and resting blood pressure: a largescale pairwise and network meta-analysis of randomised controlled trials.
- Author
-
Edwards, Jamie J., Deenmamode, Algis H. P., Griffiths, Megan, Arnold, Oliver, Cooper, Nicola J., Wiles, Jonathan D., and O'Driscoll, Jamie M.
- Published
- 2023
- Full Text
- View/download PDF
19. Critical care nursing workforce in crisis: A discussion paper examining contributing factors, the impact of the COVID‐19 pandemic and potential solutions.
- Author
-
Vogt, Katharina Sophie, Simms‐Ellis, Ruth, Grange, Angela, Griffiths, Megan Elizabeth, Coleman, Rebecca, Harrison, Reema, Shearman, Nathan, Horsfield, Claire, Budworth, Luke, Marran, Jayne, and Johnson, Judith
- Subjects
PSYCHOLOGICAL burnout ,WELL-being ,INTENSIVE care nursing ,SOCIAL support ,CHANGE management ,HEALTH facility administration ,POST-traumatic stress disorder ,FLEXTIME ,CRITICAL care nurses ,RISK assessment ,LABOR turnover ,EMPLOYEE assistance programs ,ORGANIZATIONAL change ,INDUSTRIAL hygiene ,COVID-19 pandemic ,PSYCHOLOGICAL resilience ,EMPLOYEE retention ,HOSPITAL administration - Abstract
Aims and Objectives: The critical care nursing workforce is in crisis, with one‐third of critical care nurses worldwide intending to leave their roles. This paper aimed to examine the problem from a wellbeing perspective, offering implications for research, and potential solutions for organisations. Design: Discursive/Position paper. Method: The discussion is based on the nursing and wellbeing literature. It is guided by the authors' collaborative expertise as both clinicians and researchers. Data were drawn from nursing and wellbeing peer‐reviewed literature, such as reviews and empirical studies, national surveys and government and thinktank publications/reports. Results: Critical care nurses have been disproportionately affected by the COVID‐19 pandemic with studies consistently showing critical care nurses to have the worst psychological outcomes on wellbeing measures, including depression, burnout and post‐traumatic stress disorder (PTSD). These findings are not only concerning for the mental wellbeing of critical care nurses, they also raise significant issues for healthcare systems/organisations: poor wellbeing, increased burnout and PTSD are directly linked with critical care nurses intending to leave the profession. Thus, the wellbeing of critical care nurses must urgently be supported. Resilience has been identified as a protective mechanism against the development of PTSD and burnout, thus offering evidence‐based interventions that address resilience and turnover have much to offer in tackling the workforce crisis. However, turnover data must be collected by studies evaluating resilience interventions, to further support their evidence base. Organisations cannot solely rely on the efficacy of these interventions to address their workforce crisis but must concomitantly engage in organisational change. Conclusions: We conclude that critical care nurses are in urgent need of preventative, evidence‐based wellbeing interventions, and make suggestions for research and practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Low‐affinity insulin‐like growth factor binding protein 7 and its association with pulmonary arterial hypertension severity and survival.
- Author
-
Torres, Guillermo, Lancaster, Andrew C., Yang, Jun, Griffiths, Megan, Brandal, Stephanie, Damico, Rachel, Vaidya, Dhananjay, Simpson, Catherine E., Martin, Lisa J., Pauciulo, Michael W., Nichols, William C., Ivy, David D., Austin, Eric D., Hassoun, Paul M., and Everett, Allen D.
- Abstract
Insulin‐like growth factor (IGF) binding proteins (IGFBPs) are a family of growth factor modifiers, some of which are known to be independently associated with pulmonary arterial hypertension (PAH) survival. IGF factor binding protein 7 (IGFBP7) is a unique low‐affinity IGFBP that, independent of IGF, stimulates prostacyclin production. This study proposed to establish associations between IGFBP7 and PAH severity and survival, using enrollment and longitudinal samples. Serum IGFBP7 levels were significantly elevated in patients with PAH compared to controls. After adjusting for age and sex, logarithmic increases in IGFBP7 were associated with a 20 m shorter six‐minute walk distance (6MWD; p < 0.001), a 2−3 mmHg higher mean right atrial pressure (p < 0.001 and 0.02), and a higher likelihood of a greater REVEAL 2.0 risk category placement (p < 0.001). Kaplan−Meier analysis demonstrated significantly decreased survival with IGFBP7 above the median and Cox multivariable analysis adjusted for age and sex, demonstrated higher serum IGFBP7 was an independent predictor of survival. Though the exact mechanism is still unknown, given IGFBP7's role as a prostacyclin stimulant, it has potential use as a therapeutic target for disease modulation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Intravenous prostacyclins for right ventricular failure following left ventricular assist device in paediatric heart failure.
- Author
-
Radel, Laura J., Iqbal, Mehreen, and Griffiths, Megan
- Published
- 2023
- Full Text
- View/download PDF
22. Insulin-like growth factor binding Protein-4: A novel indicator of pulmonary arterial hypertension severity and survival.
- Author
-
Torres, Guillermo, Jun Yang, Griffiths, Megan, Brandal, Stephanie, Damico, Rachel, Vaidya, Dhananjay, Simpson, Catherine E., Pauciulo, Michael W., Nichols, William C., Ivy, David D., Austin, Eric D., Hassoun, Paul M., and Everett, Allen D.
- Subjects
SOMATOMEDIN ,PULMONARY arterial hypertension ,INSULIN-like growth factor-binding proteins ,CARRIER proteins - Abstract
Proteomic analysis of patients with pulmonary arterial hypertension (PAH) has demonstrated significant abnormalities in the insulin-like growth factor axis (IGF). This study proposed to establish associations between a specific binding protein, insulin-like growth factor binding protein 4 (IGFBP4), and PAH severity as well as survival across varying study cohorts. In all cohorts studied, serum IGFBP4 levels were significantly elevated in PAH compared to controls (p < 0.0001). IGFBP4 concentration was also highest in the connective tissue-associated PAH (CTD-PAH) and idiopathic PAH subtypes (876 and 784 ng/mL, median, respectively). After adjustment for age and sex, IGFBP4 was significantly associated with worse PAH severity as defined by a decreased 6-min walk distance (6MWD), New York heart association functional class (NYHA-FC), REVEAL 2.0 score and higher right atrial pressures. In longitudinal analysis provided by one of the study cohorts, IGFBP4 was prospectively significantly associated with a shorter 6MWD, worse NYHA-FC classification, and decreased survival. Cox multivariable analysis demonstrated higher serum IGFBP4 as an independent predictor of survival in the overall PAHB cohort. Therefore, this study established that higher circulating IGFBP4 levels were significantly associated with worse PAH severity, decreased survival and disease progression. Dysregulation of IGF metabolism/growth axis may play a significant role in PAH cardio-pulmonary pathobiology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Inferring the disruption of rabies circulation in vampire bat populations using a betaherpesvirus-vectored transmissible vaccine.
- Author
-
Griffiths, Megan E., Meza, Diana K., Haydon, Daniel T., and Streicker, Daniel G.
- Subjects
- *
RABIES , *RABIES vaccines , *GENETIC vectors , *ANIMAL populations , *VAMPIRE bats , *WILD animal trade , *COST effectiveness - Abstract
Transmissible vaccines are an emerging biotechnology that hold prospects to eliminate pathogens from wildlife populations. Such vaccines would genetically modify naturally occurring, nonpathogenic viruses ("viral vectors") to express pathogen antigens while retaining their capacity to transmit. The epidemiology of candidate viral vectors within the target wildlife population has been notoriously challenging to resolve but underpins the selection of effective vectors prior to major investments in vaccine development. Here, we used spatiotemporally replicated deep sequencing to parameterize competing epidemiological mechanistic models of Desmodus rotundus betaherpesvirus (DrBHV), a proposed vector for a transmissible vaccine targeting vampire bat-transmitted rabies. Using 36 strain- and location-specific time series of prevalence collected over 6 y, we found that lifelong infections with cycles of latency and reactivation, combined with a high R0 (6.9; CI: 4.39 to 7.85), are necessary to explain patterns of DrBHV infection observed in wild bats. These epidemiological properties suggest that DrBHV may be suited to vector a lifelong, self-boosting, and transmissible vaccine. Simulations showed that inoculating a single bat with a DrBHV-vectored rabies vaccine could immunize >80% of a bat population, reducing the size, frequency, and duration of rabies outbreaks by 50 to 95%. Gradual loss of infectious vaccine from vaccinated individuals is expected but can be countered by inoculating larger but practically achievable proportions of bat populations. Parameterizing epidemiological models using accessible genomic data brings transmissible vaccines one step closer to implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. 'It came from China; it's a Chinese virus': Indexical links, social values and racist negotiations in COVID-19 representations on Twitter.
- Author
-
Lampropoulou, Sofia, Cooper, Paul, Pye, Elizabeth, and Griffiths, Megan
- Subjects
SOCIAL values ,NEGOTIATION ,COVID-19 pandemic ,RACISM ,COVID-19 ,MICROBLOGS - Abstract
This study examines the negotiations of racism by Twitter users in the representation of the COVID-19 crisis during the first wave of the pandemic. We focus on expressions that target China as the place where COVID originated such as 'Chinese virus' and 'Kung flu'. The repeated use and discussion of these terms on social media serves to create, establish and reinforce indexical links (Silverstein 2003) to social values, which relate to ideological conceptions of China and Chinese culture. Additionally, Twitter users' crisis processing involves the renegotiatation of indexical links to social values that coincides with the engagement in sociopolitical debates that frequent online media environments, resulting in sociological fractionation (Agha 2007); the ideological opposition between Twitter user groups involves statements such as 'Kung flu is racist but COVID originated in China's dirty markets.' We see such disclaimers as examples of 'liquid racism' (Weaver 2011) that, while they are difficult to pin down as racist, they naturalise Sinophobia as the dominant discourse in our dataset. We conclude that racism in our data is a resource embedded in blame attribution that is compatible with crisis processing. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. THREADS OF SURVIVAL.
- Author
-
Griffiths, Megan
- Published
- 2022
- Full Text
- View/download PDF
26. Longitudinal deep sequencing informs vector selection and future deployment strategies for transmissible vaccines.
- Author
-
Griffiths, Megan E., Broos, Alice, Bergner, Laura M., Meza, Diana K., Suarez, Nicolas M., da Silva Filipe, Ana, Tello, Carlos, Becker, Daniel J., and Streicker, Daniel G.
- Subjects
- *
RABIES , *CROSS reactions (Immunology) , *VACCINE trials , *VACCINES , *VACCINATION coverage , *VACCINE development - Abstract
Vaccination is a powerful tool in combating infectious diseases of humans and companion animals. In most wildlife, including reservoirs of emerging human diseases, achieving sufficient vaccine coverage to mitigate disease burdens remains logistically unattainable. Virally vectored "transmissible" vaccines that deliberately spread among hosts are a potentially transformative, but still theoretical, solution to the challenge of immunising inaccessible wildlife. Progress towards real-world application is frustrated by the absence of frameworks to guide vector selection and vaccine deployment prior to major in vitro and in vivo investments in vaccine engineering and testing. Here, we performed deep sequencing on field-collected samples of Desmodus rotundus betaherpesvirus (DrBHV), a candidate vector for a transmissible vaccine targeting vampire bat–transmitted rabies. We discovered 11 strains of DrBHV that varied in prevalence and geographic distribution across Peru. The phylogeographic structure of DrBHV strains was predictable from both host genetics and landscape topology, informing long-term DrBHV-vectored vaccine deployment strategies and identifying geographic areas for field trials where vaccine spread would be naturally contained. Multistrain infections were observed in 79% of infected bats. Resampling of marked individuals over 4 years showed within-host persistence kinetics characteristic of latency and reactivation, properties that might boost individual immunity and lead to sporadic vaccine transmission over the lifetime of the host. Further, strain acquisitions by already infected individuals implied that preexisting immunity and strain competition are unlikely to inhibit vaccine spread. Our results support the development of a transmissible vaccine targeting a major source of human and animal rabies in Latin America and show how genomics can enlighten vector selection and deployment strategies for transmissible vaccines. Deep sequencing of vampire bat betaherpesviruses reveals prevalent multi-strain, multi-year infections with predictable patterns of spread and no evidence of cross immunity, supporting the herpesvirus as a promising transmissible vaccine candidate for bat rabies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Proteomics discovery of pulmonary hypertension biomarkers: Insulin‐like growth factor binding proteins are associated with disease severity.
- Author
-
Nies, Melanie K., Jun Yang, Griffiths, Megan, Damico, Rachel, Jie Zhu, Vaydia, Dhananjay, Zongming Fu, Brandal, Stephanie, Austin, Eric D., Ivy, Dunbar D., Hassoun, Paul M., Van Eyk, Jennifer E., and Everett, Allen D.
- Subjects
INSULIN-like growth factor-binding proteins ,PROTEOMICS ,PULMONARY arterial hypertension ,BIOMARKERS ,FALSE discovery rate ,PULMONARY hypertension - Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by sustained elevations of pulmonary artery pressure. To date, we lack circulating, diagnostic, and prognostic markers that correlate to clinical and functional parameters. In this study, we performed mass spectrometry‐based proteomics analysis to identify circulating biomarkers of PAH. Plasma samples from patients with idiopathic pulmonary arterial hypertension (IPAH, N=9) and matched normal controls (N = 9) were digested with trypsin and analyzed using data‐dependent acquisition on an Orbitrap mass spectrometer. A total of 826 (false discovery rate [FDR] 0.047) and 461 (FDR 0.087) proteins were identified across all plasma samples obtained from IPAH and control subjects, respectively. Of these, 153 proteins showed >2 folds change (p < 0.05) between groups. Circulating levels of carbonic anhydrase 2 (CA2), plasma kallikrein (KLKB1), and the insulin‐like growth factor binding proteins (IGFBP1‐7) were quantified by immunoassay in an independent verification cohort (N=36 PAH and N = 35 controls). CA2 and KLKB1 were significantly different in PAH versus control but were not associated with any functional or hemodynamic measurements. Whereas, IGFBP1 and 2 were associated with higher pulmonary vascular resistance, IGFBP2, 4, and 7 with decreased 6‐min walk distance (6MWD), and IGFBP1, 2, 4, and 7 with worse survival. This plasma proteomic discovery analysis suggests the IGF axis may serve as important new biomarkers for PAH and play an important role in PAH pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Hepatoma‐derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival.
- Author
-
Yang, Jun, Ambade, Anjira S., Nies, Melanie, Griffiths, Megan, Damico, Rachel, Vaidya, Dhananjay, Brandal, Stephanie, Pauciulo, Michael W., Lutz, Katie A., Coleman, Anna W., Nichols, William C., Austin, Eric D., Ivy, Dunbar, Hassoun, Paul M., and Everett, Allen D.
- Subjects
VASCULAR remodeling ,PULMONARY arterial hypertension ,CONNECTIVE tissues ,SMOOTH muscle ,PULMONARY artery ,PULMONARY hypertension - Abstract
Hepatoma‐derived growth factor (HDGF) was previously shown to be associated with increased mortality in a small study of idiopathic and connective tissue disease‐associated pulmonary arterial hypertension (PAH). In this study, we measured serum HDGF levels in a large multicenter cohort (total 2017 adult PAH‐Biobank enrollees), we analyzed the associations between HDGF levels and various clinical measures using linear or logistic regression models. Higher HDGF levels were found to be significantly associated with worse pulmonary hemodynamics, prostacyclin treatment; among PAH subtypes, higher HDGF levels were most associated with portopulmonary hypertension (beta = 0.469, p < 0.0001). Both Kaplan–Meier curve and Cox proportional hazard regression demonstrated that higher HDGF levels are associated with a higher risk of mortality (COX hazard ratio 1.31, p < 0.0001). Further, in the Sugen hypoxia (SuHx) rat model, the highest HDGF levels were post‐pulmonary circulation, and HDGF levels significantly increased with the development of PAH. In pulmonary arteries, immunohistochemistry staining showed that HDGF was highly expressed in pulmonary smooth muscle cells in both PAH patients and SuHx rats. In conclusion, we found that higher serum HDGF was linked with increased mortality, and associated with disease severity in a large multi‐center adult PAH cohort (n = 2017). In the SuHX PAH models, circulating HDGF levels are pulmonary in origin and increase with PAH progression. HDGF may be actively involved in vascular remodeling in PAH. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension.
- Author
-
Daly, Caroline M., Griffiths, Megan, Simpson, Catherine E., Jun Yang, Damico, Rachel L., Vaidya, R. Dhananjay, Williams, Monica, Brandal, Stephanie, Pei-Ni Jone, Polsen, Cassandra, Ivy, D. Dunbar, Austin, Eric D., Nichols, William C., Pauciulo, Michael W., Lutz, Katie, Nies, Melanie K., Rosenzweig, Erika B., Hirsch, Russel, Yung, Delphine, and Everett, Allen D.
- Published
- 2021
- Full Text
- View/download PDF
30. Infographic. Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials.
- Author
-
Edwards, Jamie J., Deenmamode, Algis H. P., Griffiths, Megan, Arnold, Oliver, Cooper, Nicola J., Wiles, Jonathan D., and O'Driscoll, Jamie M.
- Published
- 2023
- Full Text
- View/download PDF
31. Perinatal Inflammatory Biomarkers and Respiratory Disease in Preterm Infants.
- Author
-
Collaco, Joseph M., McGrath-Morrow, Sharon A., Griffiths, Megan, Chavez-Valdez, Raul, Parkinson, Charlamaine, Zhu, Jie, Northington, Frances J., Graham, Ernest M., and Everett, Allen D.
- Abstract
Objective: To measure plasma levels of vascular endothelial growth factor (VEGF) and several cytokines (Interleukin [IL]-6 IL-8, IL-10) during the first week of life to examine the relationship between protein expression and likelihood of developing respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD).Study Design: Levels of IL-6, IL-8, IL-10, and VEGF were measured from plasma obtained from preterm patients during the first week of life. Newborns were recruited from a single center between April 2009 and April 2019. Criteria for the study included being inborn, birth weight of less than 1500 grams, and a gestational age of less than 32 weeks at birth.Results: The development of RDS in preterm newborns was associated with lower levels of VEGF during the first week of life. Higher plasma levels of IL-6 and IL-8 plasma were associated with an increased likelihood and increased severity of BPD at 36 weeks postmenstrual age. In contrast, plasma levels of VEGF, IL-6, IL-8, and IL-10 obtained during the first week of life were not associated with respiratory symptoms and acute care use in young children with BPD in the outpatient setting.Conclusions: During the first week of life, lower plasma levels of VEGF was associated with the diagnosis of RDS in preterm infants. Preterm infants with higher levels of IL-6 and IL-8 during the first week of life were also more likely to be diagnosed with BPD. These biomarkers may help to predict respiratory morbidities in preterm newborns during their initial hospitalization. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
32. Should positive end-expiratory pressure be used during elective general anaesthesia with supraglottic airway devices?
- Author
-
Griffiths, Megan, Everson, James, and Mandour, Yasser
- Abstract
Anaesthetists' use of positive end-expiratory pressure during elective general anaesthesia via supraglottic airway devices varies. Positive end-expiratory pressure may help to maintain oxygenation and prevent atelectasis, but could worsen the risk of air leak, gastric insufflation and catastrophic aspiration. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension.
- Author
-
Griffiths, Megan, Yang, Jun, Vaidya, Dhananjay, Nies, Melanie, Brandal, Stephanie, Ivy, D. Dunbar, Hickey, Francis, Wolter-Warmerdam, Kristine, Austin, Eric D., Mullen, Mary, Pauciulo, Michael W., Lutz, Katie A., Rosenzweig, Erika B., Hirsch, Russel, Yung, Delphine, Nichols, William C., and Everett, Allen D.
- Abstract
Objective: To evaluate the performance of pulmonary hypertension (PH) biomarkers in children with Down syndrome, an independent risk factor for PH, in whom biomarker performance may differ compared with other populations.Study Design: Serum endostatin, interleukin (IL)-1 receptor 1 (ST2), galectin-3, N-terminal pro hormone B-natriuretic peptide (NT-proBNP), IL-6, and hepatoma-derived growth factor (HDGF) were measured in subjects with Down syndrome and PH (n = 29), subjects with Down syndrome and resolved PH (n = 13), subjects with Down syndrome without PH (n = 49), and subjects without Down syndrome with World Symposium on Pulmonary Hypertension group I pulmonary arterial hypertension (no Down syndrome PH group; n = 173). Each biomarker was assessed to discriminate PH in Down syndrome. A classification tree was created to distinguish PH from resolved PH and no PH in children with Down syndrome.Results: Endostatin, galectin-3, HDGF, and ST2 were elevated in subjects with Down syndrome regardless of PH status. Not all markers differed between subjects with Down syndrome and PH and subjects with Down syndrome and resolved PH. NT-proBNP and IL-6 levels were similar in the Down syndrome with PH group and the no Down syndrome PH group. A classification tree identified NT-proBNP and galectin-3 as the best markers for sequentially distinguishing PH, resolved PH, and no PH in subjects with Down syndrome.Conclusions: Proteomic markers are used to improve the diagnosis and prognosis of PH but, as demonstrated here, can be altered in genetically unique populations such as individuals with Down syndrome. This further suggests that clinical biomarkers should be evaluated in unique groups with the development of population-specific nomograms. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Multiple biomarkers are equivalent to clinical pulmonary arterial hypertension survival risk models.
- Author
-
Griffiths M, Simpson CE, Yang J, Vaidya D, Nies MK, Brandal S, Damico R, Hassoun P, Ivy DD, Austin ED, Pauciulo MW, Lutz KA, Martin LJ, Rosenzweig EB, Benza RL, Nichols WC, Manlhiot C, and Everett AD
- Abstract
Background: Risk assessment in pulmonary arterial hypertension (PAH) is fundamental to guiding treatment and improved outcomes. Clinical models are excellent at identifying high-risk patients but leave uncertainty amongst moderate risk patients., Research Question: Can a multiple blood biomarker model of PAH, using previously described biomarkers, improve risk discrimination over current models?, Study Design and Methods: Using multiplex ELISA, we measured NT-proBNP, ST2, IL-6, Endostatin, Galectin-3, HDGF, and IGF binding proteins (IGFBP1-7) in train (n=1623), test (n=696) and validation (n=237) cohorts. Clinical variables, biomarkers were evaluated by principal component analysis. NT-proBNP was not included to develop an NT-proBNP independent model. Unsupervised k-means clustering classified subjects into clusters. Transplant-free survival by cluster was examined using Kaplan-Meier and Cox proportional hazard regressions. Hazard by cluster was compared to NT-proBNP, REVEAL, and ESC/ERS Risk models alone, and combined clinical and biomarker models., Results: The algorithm generated 5 clusters with good risk discrimination using 6 biomarkers, weight, height, and age at PAH diagnosis. In the test and validation cohorts the biomarker model alone performed equivalent to REVEAL (AUC 0.74). Adding the biomarker model to the ESC/ERS, and REVEAL scores improved the ESC/ERS and REVEAL scores. The best overall model was the biomarker model adjusted for NT-proBNP with the best C-statistic, AIC, and calibration for the adjusted model compared to either the biomarker or NT-proBNP model alone., Interpretation: A multi-biomarker model alone was equivalent to current PAH clinical mortality risk prediction models and improved performance when combined, and added to NT-proBNP. Clinical risk scores offer excellent predictive models but require multiple tests; adding blood biomarkers to models can improve prediction or enable more frequent, non-invasive monitoring of risk in PAH to support therapeutic decision making., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
35. Advances in understanding bat infection dynamics across biological scales.
- Author
-
Sánchez CA, Phelps KL, Frank HK, Geldenhuys M, Griffiths ME, Jones DN, Kettenburg G, Lunn TJ, Moreno KR, Mortlock M, Vicente-Santos A, Víquez-R LR, Kading RC, Markotter W, Reeder DM, and Olival KJ
- Subjects
- Humans, Animals, Livestock, Chiroptera
- Abstract
Over the past two decades, research on bat-associated microbes such as viruses, bacteria and fungi has dramatically increased. Here, we synthesize themes from a conference symposium focused on advances in the research of bats and their microbes, including physiological, immunological, ecological and epidemiological research that has improved our understanding of bat infection dynamics at multiple biological scales. We first present metrics for measuring individual bat responses to infection and challenges associated with using these metrics. We next discuss infection dynamics within bat populations of the same species, before introducing complexities that arise in multi-species communities of bats, humans and/or livestock. Finally, we outline critical gaps and opportunities for future interdisciplinary work on topics involving bats and their microbes.
- Published
- 2024
- Full Text
- View/download PDF
36. Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect.
- Author
-
Bull JJ, Nuismer SL, Remien CH, Griffiths ME, and Antia R
- Subjects
- Humans, Animals, Zoonoses prevention & control, Vaccines, Synthetic genetics, Superinfection, Rabies prevention & control, Rabies Vaccines genetics, Viruses
- Abstract
Introduction: Transmissible vaccines offer a novel approach to suppressing viruses in wildlife populations, with possible applications against viruses that infect humans as zoonoses - Lassa, Ebola, rabies. To ensure safety, current designs propose a recombinant vector platform in which the vector is isolated from the target wildlife population. Because using an endemic vector creates the potential for preexisting immunity to block vaccine transmission, these designs focus on vector viruses capable of superinfection, spreading throughout the host population following vaccination of few individuals., Areas Covered: We present original theoretical arguments that, regardless of its R
0 value, a recombinant vaccine using a superinfecting vector is not expected to expand its active infection coverage when released into a wildlife population that already carries the vector. However, if superinfection occurs at a high rate such that individuals are repeatedly infected throughout their lives, the immunity footprint in the population can be high despite a low incidence of active vaccine infections. Yet we provide reasons that the above expectation is optimistic., Expert Opinion: High vaccine coverage will typically require repeated releases or release into a population lacking the vector, but careful attention to vector choice and vaccine engineering should also help improve transmissible vaccine utility.- Published
- 2024
- Full Text
- View/download PDF
37. Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials.
- Author
-
Edwards JJ, Deenmamode AHP, Griffiths M, Arnold O, Cooper NJ, Wiles JD, and O'Driscoll JM
- Subjects
- Humans, Antihypertensive Agents, Blood Pressure physiology, Exercise physiology, Network Meta-Analysis, Randomized Controlled Trials as Topic, Hypertension prevention & control
- Abstract
Objective: To perform a large-scale pairwise and network meta-analysis on the effects of all relevant exercise training modes on resting blood pressure to establish optimal antihypertensive exercise prescription practices., Design: Systematic review and network meta-analysis., Data Sources: PubMed (Medline), the Cochrane library and Web of Science were systematically searched., Eligibility Criteria: Randomised controlled trials published between 1990 and February 2023. All relevant work reporting reductions in systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) following an exercise intervention of ≥2 weeks, with an eligible non-intervention control group, were included., Results: 270 randomised controlled trials were ultimately included in the final analysis, with a pooled sample size of 15 827 participants. Pairwise analyses demonstrated significant reductions in resting SBP and DBP following aerobic exercise training (-4.49/-2.53 mm Hg, p<0.001), dynamic resistance training (-4.55/-3.04 mm Hg, p<0.001), combined training (-6.04/-2.54 mm Hg, p<0.001), high-intensity interval training (-4.08/-2.50 mm Hg, p<0.001) and isometric exercise training (-8.24/-4.00 mm Hg, p<0.001). As shown in the network meta-analysis, the rank order of effectiveness based on the surface under the cumulative ranking curve (SUCRA) values for SBP were isometric exercise training (SUCRA: 98.3%), combined training (75.7%), dynamic resistance training (46.1%), aerobic exercise training (40.5%) and high-intensity interval training (39.4%). Secondary network meta-analyses revealed isometric wall squat and running as the most effective submodes for reducing SBP (90.4%) and DBP (91.3%), respectively., Conclusion: Various exercise training modes improve resting blood pressure, particularly isometric exercise. The results of this analysis should inform future exercise guideline recommendations for the prevention and treatment of arterial hypertension., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
38. COL18A1 genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study.
- Author
-
Simpson CE, Griffiths M, Yang J, Nies MK, Vaidya D, Brandal S, Martin LJ, Pauciulo MW, Lutz KA, Coleman AW, Austin ED, Ivy DD, Nichols WC, Everett AD, Hassoun PM, and Damico RL
- Abstract
Variation around the COL18A1 gene, which encodes the angiostatic peptide endostatin, may influence disease heterogeneity in pulmonary arterial hypertension https://bit.ly/3shXrNR., Competing Interests: Conflict of interest: C.E. Simpson reports support for the present manuscript received from NIH/NHLBI grants. Conflict of interest: M. Griffiths reports support for the present manuscript received from NIH/NHLBI grants. Conflict of interest: J. Yang has nothing to disclose. Conflict of interest: M.K. Nies has nothing to disclose. Conflict of interest: D. Vaidya reports receiving grants or contacts outside the submitted work from National Institutes of Health. Conflict of interest: S. Brandal has nothing to disclose. Conflict of interest: L.J. Martin reports support for the present manuscript received from NIH/NHLBI grants. Conflict of interest: M.W. Pauciulo has nothing to disclose. Conflict of interest: K.A. Lutz has nothing to disclose. Conflict of interest: A.W. Coleman has nothing to disclose. Conflict of interest: E.D. Austin reports support for the present manuscript received from NIH/NHLBI grants; and grants or contracts received from CMREF, outside the submitted work. Conflict of interest: D.D. Ivy reports support for the present manuscript received from NIH/NHLBI grants; and consulting fees received from The University of Colorado contracts with Actelion, Altavant, Bayer, and Gossamer Bio, outside the submitted work. Conflict of interest: W.C. Nichols reports support for the present manuscript received from NIH/NHLBI grants. Conflict of interest: A.D. Everett reports support for the present manuscript received from NIH/NHLBI grants. Conflict of interest: P.M. Hassoun reports receiving grants or contacts outside the submitted work from NIH/NHLBI; and he serves on a scientific Advisory Board for MSD, unrelated to the current work. Conflict of interest: R.L. Damico reports support for the present manuscript received from NIH/NHLBI grants., (Copyright ©The authors 2022.)
- Published
- 2022
- Full Text
- View/download PDF
39. The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension.
- Author
-
Simpson CE, Griffiths M, Yang J, Nies MK, Vaidya RD, Brandal S, Martin LJ, Pauciulo MW, Lutz KA, Coleman AW, Austin ED, Ivy DD, Nichols WC, Everett AD, Hassoun PM, and Damico RL
- Abstract
Currently available noninvasive markers for assessing disease severity and mortality risk in pulmonary arterial hypertension (PAH) are unrelated to fundamental disease biology. Endostatin, an angiostatic peptide known to inhibit pulmonary artery endothelial cell migration, proliferation and survival in vitro , has been linked to adverse haemodynamics and shortened survival in small PAH cohorts. This observational cohort study sought to assess: 1) the prognostic performance of circulating endostatin levels in a large, multicentre PAH cohort; and 2) the added value gained by incorporating endostatin into existing PAH risk prediction models. Endostatin ELISAs were performed on enrolment samples collected from 2017 PAH subjects with detailed clinical data, including survival times. Endostatin associations with clinical variables, including survival, were examined using multivariable regression and Cox proportional hazards models. Extended survival models including endostatin were compared to null models based on the REVEAL risk prediction tool and European Society of Cardiology/European Respiratory Society (ESC/ERS) low-risk criteria using likelihood ratio tests, Akaike and Bayesian information criteria and C-statistics. Higher endostatin was associated with higher right atrial pressure, mean pulmonary arterial pressure and pulmonary vascular resistance, and with shorter 6-min walk distance (p<0.01). Mortality risk doubled for each log higher endostatin (hazard ratio 2.3, 95% CI 1.6-3.4, p<0.001). Endostatin remained an independent predictor of survival when incorporated into existing risk prediction models. Adding endostatin to REVEAL-based and ESC/ERS criteria-based risk assessment strategies improved mortality risk prediction. Endostatin is a robust, independent predictor of mortality in PAH. Adding endostatin to existing PAH risk prediction strategies improves PAH risk assessment., Competing Interests: Conflict of interest: C.E. Simpson has nothing to disclose. Conflict of interest: M. Griffiths has nothing to disclose. Conflict of interest: J. Yang has nothing to disclose. Conflict of interest: M.K. Nies has nothing to disclose. Conflict of interest: R.D. Vaidya has nothing to disclose. Conflict of interest: S. Brandal has nothing to disclose. Conflict of interest: L.J. Martin reports grants from the NIH during the conduct of the study. Conflict of interest: M.W. Pauciulo has nothing to disclose. Conflict of interest: K.A. Lutz has nothing to disclose. Conflict of interest: A.W. Coleman has nothing to disclose. Conflict of interest: E.D. Austin reports grants from the NIH/NHLBI during the conduct of the study. Conflict of interest: The University of Colorado has contracts with Actelion, Bayer, GSK, Lilly, Liquidia and United Therapeutics for D.D. Ivy to be a consultant and to perform clinical trials. D.D. Ivy has received money for travel and lodging from Bayer, and food and beverages from United Therapeutics. Conflict of interest: W.C. Nichols has nothing to disclose. Conflict of interest: A.D. Everett has a patent (Biomarkers of Pulmonary Hypertension) pending. Conflict of interest: P.M. Hassoun served on a scientific advisory board for Merck & Co. Conflict of interest: R.L. Damico has nothing to disclose., (Copyright ©The authors 2021.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.